Table 3

Treatment results according to CD56 expression

CharacteristicCD56-positive
CD56-negative
P
No. of patients%No. of patients%
Overall 72 100 579* 100  
Induction outcome      
    Complete remission 61 85 534 92 .04 
    Causes of induction death      
        Hemorrhage 5 6.9 26 4.5 .53 
        Infection 3 4.2 11 1.9 .41 
        Differentiation syndrome 1 1.4 5 0.9 .99 
        Thrombosis/infarction 2 2.8 2 0.4 .09 
Differentiation syndrome†      
    Severe 11 16 69 12 .69 
    Moderate 10 14 80 14  
    Absent 49 70 417 74  
Postremission outcomes at 5 y      
    CIR  22  10 .006 
    CIR (extramedullary)  7.0  0.7 < .001 
    Disease-free survival  73  85 .03 
    Overall survival  78  84 .09 
CharacteristicCD56-positive
CD56-negative
P
No. of patients%No. of patients%
Overall 72 100 579* 100  
Induction outcome      
    Complete remission 61 85 534 92 .04 
    Causes of induction death      
        Hemorrhage 5 6.9 26 4.5 .53 
        Infection 3 4.2 11 1.9 .41 
        Differentiation syndrome 1 1.4 5 0.9 .99 
        Thrombosis/infarction 2 2.8 2 0.4 .09 
Differentiation syndrome†      
    Severe 11 16 69 12 .69 
    Moderate 10 14 80 14  
    Absent 49 70 417 74  
Postremission outcomes at 5 y      
    CIR  22  10 .006 
    CIR (extramedullary)  7.0  0.7 < .001 
    Disease-free survival  73  85 .03 
    Overall survival  78  84 .09 

CIR indicates cumulative incidence of relapse.

*

One patient among the CD56− cohort was considered as resistant.

†

A total of 636 patients were evaluable for differentiation syndrome.

View Large
Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal